Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial

BACKGROUND: This first-in-human phase 1 trial is to evaluate the safety, pharmacokinetics, preliminary efficacy, and biomarkers of sugemalimab, a full-length, fully human anti-PD-L1 monoclonal antibody, in Chinese patients with advanced malignancies. METHODS: Eligible patients with unresectable adva...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jifang, Cao, Junning, Zhang, Qingyuan, Xu, Nong, Zhao, Yanqiu, Xing, Baocai, Miao, Zhanhui, Wu, Yilong, Pan, Hongming, Gao, Quanli, Li, Xingya, Liu, Baorui, Li, Wei, Pei, Zhidong, Xia, Hongqiang, Qi, Qinzhou, Dai, Hangjun, Shi, Qingmei, Yang, Jianxin, Li, Jin, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293819/
https://www.ncbi.nlm.nih.gov/pubmed/34984540
http://dx.doi.org/10.1007/s00262-021-03102-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293819/
https://www.ncbi.nlm.nih.gov/pubmed/34984540
http://dx.doi.org/10.1007/s00262-021-03102-3

Ejemplares similares